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Background
Acute Coronary Syndrome (ACS) imposes a major burden on the US healthcare system. There were 1.14 million hospitalizations for ACS in 2010, and the annual medical cost for each commercially insured case ranged between $34,000 and $87,000 depending on the initial treatment.
1,2 Surgical intervention is important to reduce cardiovascular complications. [2] [3] [4] [5] Further, across the wide spectrum of ACS care options, the use of anti-platelet therapy along with aspirin administration, referred to as dual anti-platelet therapy (DAPT), is a key recommendation in the prevention of the secondary events.
3,5
Anti-platelet management in ACS care has progressed substantially over the last two decades. In 1997, the Food and Drug Administration (FDA) approved clopidogrel for the secondary prevention of cardiovascular events, and it experienced continuous growth in utilization. [6] [7] [8] [9] [10] Recently, ACS care evolved with approvals of 3 rd -generation oral anti-platelet therapies including prasugel and ticagrelor which are commonly indicated as an adjunct to percutaneous coronary intervention (PCI) for a diagnosis of ACS. 11, 12 In randomized trials, both prasugrel and ticagrelor reduced the risk of the composite endpoint of myocardial infarction, stroke, and cardiovascular death compared to clopidogrel. 13, 14 Further, using prasugrel or ticagrelor was cost-effective in comparison to the historic gold standard. 15, 16 Corresponding to all the evidence, clinical guidelines were updated with recommendations on using the recently approved agents. 3, 5, [17] [18] [19] A recent study showed that the proportion of patients using prasugrel increased from 3% in October 2009 to 18% in September 2012 in patients with ST-elevation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI). However, because ticagrelor was not included in this study, it is unclear how the availability of the third agent impacted the choice of anti-platelet agents. In addition, the results from the National Cardiovascular Registry may not be generalizable to national practice since being enrolled in the program is voluntary, which makes it more likely to reflect clinical practices that would adhere to guidelines.
The objective of our analysis was to describe trends in the use of three oral anti-platelet agents in commercially insured ACS patients who have newly received PCI.
Methods
Data Sources
Paid claims for a commercially insured population were obtained from Truven Health Analytics.
The 
Study Design and Analytic Cohort
A time-series analysis was performed for the patients who initiated one of the oral anti-platelet agents for post ACS-PCI care. Patients who were discharged from a hospitalization with a primary diagnosis of ACS (ICD-9-CM: 410.xx [except 410.x2], 411.1x, and 411.8x) between July 2009 and December 2013 were identified, and their PCI procedures during the hospitalization were determined using ICD-9 codes and Current Procedural Terminology codes. Of the ACS-PCI subjects, patients who initiated clopidogrel, prasugrel or ticagrelor within 14 days from the date of discharge were included in the analytic cohort. In order to avoid misinterpretation of the intended switching between loading and maintenance uses, the analytic cohort also excluded patients who received two or more different antiplatelet agents during the 14-day assessment period. To focus on new users, we excluded patients who had received any anti-platelet medication during the 6-month prior to the ACS-PCI admission. [21] [22] [23] Over the same baseline period, medical history that potentially influenced the selection of an anti-platelet agent were collected using ICD-9-CM codes. [24] [25] [26] [27] [28] . For example, a past diagnosis of cerebrovascular encounter needs to be assessed before determining the medication strategy. 3, 5, 6, 11, 12 Underlying myocardial infarction and other key comorbidities were also collected using a known coding algorithm for defining Charlson
Comorbidities.
Statistical Approach
We used descriptive statistics segmented by calendar time to summarize the use of the three medications. The primary variable used in describing trends in new medication adoption was the monthly number and proportion of patients who newly initiated one of the oral anti-platelet agents. In addition to the proportions, the 95% confidence intervals of the changes in the proportion were projected using a standard bootstrap re-sampling percentile approach with one thousand replicates.
In order to provide additional insight into the use of these drugs, differences in patient characteristics across the three drug groups were compared. Predictors in the selection between 3 rd -generation agents vs. clopidogrel, and between ticagrelor vs. prasugrel were examined using logistic regression model adjusted for the semi-annually segmented period and geographic location. Patient factors for consideration in the regression model were selected from the baseline characteristics whose p-value in a bivariate analysis was less than 0.1. Independent variable selection was then performed using a stepwise forward selection approach with significance levels for entering effects of 0.1 and for the removing effect of 0.05. All of the statistical analysis was performed using SAS software version 9.3 (SAS Institute, Cary, NC).
Results
A total of 66,335 anti-platelet agent initiations over the 4.5 year period were identified. Of them, approved, and 85% of those cases were clopidogrel users. From July 2011 to the end of 2013, 68%, 25%
and 7% of the overall cohort were clopidogrel, prasugrel and ticagrelor initiators, respectively. The average proportion of patients with a STEMI diagnosis was higher in those on prasugrel or ticagrelor than the percentage in the clopiodgrel group (57.1% vs. 50. 5 %, p<0.01). When we compared clopidogrel users to 3 rd -generation agents, the proportions of patients having a history of a cardiovascular disorder including MI (9.1% vs. 8.2%), ischemic stroke (1.7% vs. 0.7%), intra-(0.16% vs. 0.07%) and extra-cerebrovascular bleedings (7.0% vs. 5.5%) were significantly (p<0.05) higher in patients treated with clopidogrel. Also, the patients on newer agents were younger than the clopidogrel patients, with The analysis identified a sizable number using the newer anti-platelet agents with a history of conditions in which use of those agents are recommended to be avoided. Of the 13,609 subjects starting prasugrel, 268 (1.97%) were equal to or greater 75 years old. Of them, 167 (1.77% of the prasugrel patients) did not report a diagnosis of MI or diabetes over the baseline assessment period. The number of patients having a history of ischemic stroke or TIA were 1,643, and 146 of them received prasugrel, which was also not a recommended use of the drug. With regard to the risk of bleeding, a total of 12 of the prasugrel or ticagrelor users had a prior history of a cerebrovascular hemorrhage.
Discussion
This study describes broad trends of early anti-platelet agent use among commercially insured patients following PCI. While clopidogrel was used in the majority of the patients across the entire study period, an increase in the initiation of ticagrelor corresponded to a decrease in the use of prasugrel, resulting in the total percentage of patients starting the newer agents remaining constant. The results suggest a maximum loss of the clopidogrel market share beyond which the 3 rd -generation agents could not gain more. Recent evaluations demonstrated that prasugrel and ticagrelor achieved an incremental cost per quality adjusted life years gain of less than $100,000, and a genotype guided therapy enabled the inclusion of the two new agents to be more cost-effective. 31-33 However, whether the high cost of the newer agents offset by better clinical outcomes has been under-investigated in real-world populations.
Regarding this, the National Average Drug Acquisition Costs shows that the acquisition cost of generic clopidogrel 75mg tablet was as low as $0.08 per day which was more than 100 times less than the daily cost of ticagrelor or prasugrel. 34 Similarly, the cost of clopidogrel in previous economic evaluations was also 45 to 70 times lower than that of the newer agents. 16, 33 Whether this high cost of medication was a barrier which cannot be paid off by the better effectiveness needs to be investigated further.
Of the patients using a 3 rd -generation agent, ticagrelor gradually replaced prasugrel share and reached 47% of the total 3 rd -generation anti-platelet agent use in December 2013. In the replacement of prasugrel with ticagrelor, contraindications in the use of prasugrel such as older age and cerebrovascular events acted as determinants. However, patients with age ≥ 75 were 11% of the total ticagrelor use, and those who have a history of ischemic stroke or TIA accounted for only 2% of the total ticagrelor initiators, meaning that the replacement was not limited to conditions in which prasugrel was recommended to be avoided. Interestingly, running counter to these trends, studies using a hospital charge data master found that resource utilization over 30 to 90-day post ACS discharge decreased more with prasugrel, not ticagrelor. 35, 36 Whether drug use in the near future will echo the observational studies is another area for investigation.
Our research provides multiple stakeholders with useful information. we determined the specific diagnosis of ACS on the basis of the ICD-9-CM algorithm that has been employed in multiple studies already. [36] [37] [38] However, there remains concern regarding the validity of the coding because insurance claims are designed for reimbursement purpose. Further, the data did not include full information regarding procedures provided during the index ACS-PCI admission, so some factors related to drug selection may not have been identified.
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